Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872386 | 1.00 | CRHBP (0.38) | CRHBPCRHR2MMP2MMP9CHRNB2 | |
| SCHEMBL30812516 | 1.00 | CRHBP (0.38) | CRHBPCRHR2MMP2MMP9CHRNB2 | |
| SCHEMBL2731860 | 0.78 | BACE1 (0.38) | BACE1 | |
| SCHEMBL2077742 | 0.77 | ATM (0.35) | MMP2MMP9CFTRGOPCCA2 | |
| SCHEMBL2513974 | 0.77 | ATM (0.35) | MMP2MMP9CFTRGOPCCA2 | |
| SCHEMBL2077738 | 0.77 | ATM (0.35) | MMP2MMP9CFTRGOPCCA2 | |
| SCHEMBL4398746 | 0.76 | CA2 (0.41) | CFTRGOPCCA2MEN1KMT2A | |
| SCHEMBL6941289 | 0.75 | TSHR (0.34) | MMP2MMP9CHRNB2SLC6A2CHRNB4 | |
| SCHEMBL5872354 | 0.74 | GAA (0.35) | MMP2MMP9CYP1A2MEN1KMT2A | |
| SCHEMBL5872352 | 0.74 | GAA (0.35) | MMP2MMP9CYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845299-B2 | Process for the preparation of a fluorolacton derivative | GILEAD PHARMASSET LLC (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170183317-A1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTION DERIVATIVE | GILEAD SCIENCES, INC. | 2017-06-29 | — | — | US | disclosed |
| US-9624183-B2 | Process for the preparation of a fluorolacton derivative | GILEAD PHARMASSET LLC (US) | 2017-04-18 | — | — | US | disclosed |
| WO-2014016766-A1 | GUANIDINE DERIVATIVES AS TRPC MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-01-30 | — | — | WO | disclosed |
| US-7126028-B1 | Process for preparing chiral compounds | THE UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWS (GB) | 2006-10-24 | — | — | US | disclosed |
| EP-1135349-A1 | PROCESS FOR PREPARING CHIRAL COMPOUNDS | UNIVERSITY OF DURHAM (GB) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000034210-A1 | PROCESS FOR PREPARING CHIRAL COMPOUNDS | UNIVERSITY OF DURHAM (GB) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183317-A1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTION DERIVATIVE | CYP3A5, CYP2F1, CYP7A1 | CRHBP 4290/4885CRHR2 4510/4885MMP2 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.